
GUTS
Fractyl Health Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.970
Open
1.920
VWAP
1.93
Vol
134.92K
Mkt Cap
94.04M
Low
1.850
Amount
260.14K
EV/EBITDA(TTM)
--
Total Shares
48.98M
EV
81.31M
EV/OCF(TTM)
--
P/S(TTM)
1.55K
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
0.00
-100%
-0.363
-15.23%
--
--
-0.360
-0%
Estimates Revision
The market is revising No Change the revenue expectations for Fractyl Health, Inc. (GUTS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 60.00%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+5.16%
In Past 3 Month
Stock Price
Go Up

+60.00%
In Past 3 Month
3 Analyst Rating

385.94% Upside
Wall Street analysts forecast GUTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GUTS is 9.33 USD with a low forecast of 6.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

385.94% Upside
Current: 1.920

Low
6.00
Averages
9.33
High
12.00

385.94% Upside
Current: 1.920

Low
6.00
Averages
9.33
High
12.00
Morgan Stanley
Michael Ulz
Buy
Maintains
$18 → $10
2025-02-03
Reason
Morgan Stanley
Michael Ulz
Price Target
$18 → $10
2025-02-03
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Fractyl Health Inc (GUTS.O) is -1.23, compared to its 5-year average forward P/E of -1.93. For a more detailed relative valuation and DCF analysis to assess Fractyl Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.93
Current PE
-1.23
Overvalued PE
-0.50
Undervalued PE
-3.37
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-2.35
Current EV/EBITDA
-1.31
Overvalued EV/EBITDA
0.37
Undervalued EV/EBITDA
-5.07
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
6415.93
Current PS
0.00
Overvalued PS
11557.41
Undervalued PS
1274.46
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
+14.93%
-24.76M
Operating Profit
FY2025Q1
YoY :
+614.48%
-23.74M
Net Income after Tax
FY2025Q1
YoY :
+345.45%
-0.49
EPS - Diluted
FY2025Q1
YoY :
+99.90%
-25.53M
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
+325.68%
-133.41K
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
685.2K
USD
6
0-12
Months
188.5K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
5
103.5K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
102.8K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
685.2K
USD
6
0-12
Months
188.5K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
5
103.5K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GUTS News & Events
Events Timeline
2025-06-23 (ET)
2025-06-23
07:49:25
Fractyl Health announces three-month data from REVEAL-1 Cohort of REMAIN-1 study

2025-06-23
07:47:34
Fractyl Health presents preclinical data on Rejuva Smart GLP-1 platform

2025-06-18 (ET)
2025-06-18
07:04:45
Fractyl Health announces USPTO issued two new patents

Sign Up For More Events
Sign Up For More Events
News
9.0
06-23BenzingaFractyl Health Stock Is Trading Lower Monday: What's Going On?
9.0
06-23NASDAQ.COMFractyl Health Reports 3-Month REVEAL-1 Data Suggesting Durable Weight Maintenance, Stock Down
9.0
06-23NewsfilterFractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
Sign Up For More News
People Also Watch

VOC
VOC Energy Trust
3.290
USD
+2.17%

DBVT
Dbv Technologies SA
9.455
USD
-3.27%

IMUX
Immunic Inc
1.120
USD
+4.67%

ENTX
Entera Bio Ltd
1.860
USD
-2.62%

XFOR
X4 Pharmaceuticals Inc
1.820
USD
-0.55%

MVO
MV Oil Trust
5.910
USD
-2.80%

OSS
One Stop Systems Inc
5.220
USD
-6.12%

VMCA
Valuence Merger Corp I
0
USD
-0.17%

AZI
Autozi Internet Technology (Global) Ltd
0.269
USD
+1.89%

IMAB
I-Mab
2.110
USD
-0.47%
FAQ

What is Fractyl Health Inc (GUTS) stock price today?
The current price of GUTS is 1.92 USD — it has increased 0.52 % in the last trading day.

What is Fractyl Health Inc (GUTS)'s business?

What is the price predicton of GUTS Stock?

What is Fractyl Health Inc (GUTS)'s revenue for the last quarter?

What is Fractyl Health Inc (GUTS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Fractyl Health Inc (GUTS)'s fundamentals?

How many employees does Fractyl Health Inc (GUTS). have?
